**March 2022**

# Annex 1: Programmatic Reporting for COVID-19 Delivery Support (CDS) grants

**Countries are required to provide the following for programmatic reporting**:

* Monthly reporting on your COVID-19 vaccination programme through the COVID-19 module of the WHO-UNICEF electronic Joint Reporting Form1;
* Activity completion rates (submitted in the same 6 monthly financial and expenditure report template provided by Gavi);
* **Complete this complementary programmatic reporting template on a 6 monthly basis** (or as specified in relevant Grant Agreement), to be submitted alongside the financial and expenditure report.
* This template is to be used to report on Gavi COVID-19 Delivery Support (CDS) Early Access grants, Needs Based grants and/or CDS3 grants.
* Report on milestones for CDS TA activities in June and November of each year on the PEF Portal. The milestones will be identified in the CDS TA plan. Guidance for designing milestones can be found here: [Instructions for CDS TA Milestones.](https://drive.google.com/file/d/16KlK_C1vXy34M-XIUdy9fmyegjocNL0a/view?usp=sharing)

**PROGRAMMATIC REPORTING TEMPLATE**

**Section 1: Select quantitative reporting against core CDS metrics (should these be relevant)**

*NB: These are complementary and not duplicative of reporting through the COVID-19 module of the WHO-UNICEF electronic Joint Reporting Form.*

|  |  |  |  |
| --- | --- | --- | --- |
| Type of Equipment [[1]](#footnote-2) | Number Procured | Number Leased | Number Installed to Date |
| Walk-in Cold Rooms and Freezer Rooms |  |  |  |
| Vaccine Fridges |  |  |  |
| Vaccine Freezers |  |  |  |
| UCC Equipment |  |  |  |

**Section 2: Key learnings related to CDS**

*We recommend the following section does not exceed more than 3 pages in text and encourage the attachment of any relevant analyses or quantitative data.*

1. What have been the most significant challenges in implementation of your CDS grant/s to date?
2. Highlight your top three results / successes linked to your CDS grant to date.

* Please provide both qualitative and quantitative data to accompany these results to the extent possible.
* Specifying which COVID-19 vaccination campaigns / number of persons reached with COVID-19 vaccination / vaccine programme milestones that CDS funds contributed to are particularly welcome.
* Insights into any successes related to innovation are encouraged.
* *If you have received funding from the CDS 3 window*, please complete the following table. The data in this table should be the same as the one included in the CDS3 application, except for the columns “Coverage reached 2022” and “Coverage reached 2023”, which are new, and that we request you complete with the latest data you have.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | Actuals at time of application (baseline) | Targets for end of 2022 | Coverage reached 2022 | Targets for end of 2023 | Coverage reached 2023 |
| High and highest risk populations | **Complete Primary Series** | Coverage of older adult\* population [Number & %] |  |  |  |  |  |
| Coverage of health care workers  [Number & %] |  |  |  |  |  |
| Coverage of *other target group/s (please specify)* |  |  |  |  |  |
| **With booster/s** | Coverage of older adult population [Number & %] |  |  |  |  |  |
| Coverage of health care workers  [Number & %] |  |  |  |  |  |
| Coverage of *other target group/s (please specify)* |  |  |  |  |  |
|  | | | **Actuals at time of application (baseline)** | **Targets for end of 2022** | **Coverage reached 2022** | **Targets for end of 2023** | **Coverage reached 2023** |
| Adult population | **Complete Primary Series** | Coverage of total adult population [Number & %] |  |  |  |  |  |
| **With booster/s** | Coverage of total adult population [Number & %] |  |  |  |  |  |

1. Please provide a short narrative / summary to explain your overall rate of utilisation of funds and activity completion as reported through your financial / expenditure report (for example, please explain\, among other topics, what strategies were put in place to reach high risk or booster population and accelerate C19 coverage – campaigns, routine, others, etc.-, How confidence in Covid19 vaccines / vaccine hesitancy/low demand generation was addressed, How the country promoted the inclusion of CSOs in C19 delivery, when applicable, how has capacity building and training of health care professionals/managers/supervisors occurred; etc.)
2. *If you have received funding from the CDS 3 window*, please complete the following table.

|  |  |  |
| --- | --- | --- |
| **Core CDS Objectives** | **Summary of utilised amount (US$)** | **High level summary of key activities** |
| 1. High risk population |  |  |
| 1. Adult Population |  |  |
| 1. C19 and RI integration |  |  |

1. As applicable, please provide a short description of the progress on the following aspects of cold chain equipment (CCE) investment through this CDS support, highlighting any challenges or delays faced (for example, how CDS contributed to maintaining or strengthening a functional cold chain and vaccine management and distribution system):

* The receipt and installation of any equipment procured through the CDS support;
* Any equipment maintenance and/or site-readiness activities;
* Any leasing or rental of cold storage services through third-party providers.

1. To what extent has Gavi-funded Technical Assistance (TA) enabled and supported your COVID-19 vaccination programme and CDS implementation? What critical gaps, if any, has the country faced in terms of TA to implement its CDS?
2. Please provide a short commentary on how and if CDS funds have been used towards strengthening broader routine immunization (beyond COVID-19) and what types of activities have supported the **integration of C19 with routine immunisation/other essential health** services, including innovative aspects that may have been supported through CDS.

1. NB : This report is specific to CCE funded under CDS (Early Access Window and Needs Based, and CDS3) only. [↑](#footnote-ref-2)